Pulse Biosciences (PLSE) said Thursday that preliminary data from its first-in-human study of nanosecond pulsed field ablation technology showed reduction in benign thyroid nodule sizes by over 50% on average.
The pulses did not leave any residual fibrosis or scarring and symptoms improved within the first month, according to the company.
The company's shares fell 3% in recent trading.
Price: 17.18, Change: -0.54, Percent Change: -3.08